Cargando…

Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis

Background: Currently, there are many different drugs to improve Alzheimer’s disease (AD) from different pathways. As a supplement and alternative medicine, traditional Chinese medicine (TCM) targets multiple pathways which may be different from classical Western medicine, which may be orchestrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Du, Xin-Yuan, Cao, Yu-Shuang, Yang, Juan, Guo, Li-Chen, Zhang, Tong, Yuan, Qing, Chen, Xi, Hu, Li-min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471869/
https://www.ncbi.nlm.nih.gov/pubmed/36120381
http://dx.doi.org/10.3389/fphar.2022.956746
_version_ 1784789178028916736
author Du, Xin-Yuan
Cao, Yu-Shuang
Yang, Juan
Guo, Li-Chen
Zhang, Tong
Yuan, Qing
Chen, Xi
Hu, Li-min
author_facet Du, Xin-Yuan
Cao, Yu-Shuang
Yang, Juan
Guo, Li-Chen
Zhang, Tong
Yuan, Qing
Chen, Xi
Hu, Li-min
author_sort Du, Xin-Yuan
collection PubMed
description Background: Currently, there are many different drugs to improve Alzheimer’s disease (AD) from different pathways. As a supplement and alternative medicine, traditional Chinese medicine (TCM) targets multiple pathways which may be different from classical Western medicine, which may be orchestrated with Western medicine to materialize multiplying efficacy in AD patients. Objective: To investigate the therapeutic effect and assess the available preclinical evidence and possible mechanisms of β-asarone which was extracted from Acorus gramineus Soland (Araceae, AGS) for AD based on rat and mouse animal models. Methods: PubMed, Embase, Scopus, Cochrane Library, BIOSIS Previews, Web of Science, EBSCO, and Google Scholar were searched from inception to 5 May 2022. Rat and mouse experiments assessing the therapeutic effects of β-asarone for AD were included. Primary outcomes were neuroethology, including escape latency and times of crossing platform. Second outcomes were cell apoptosis, including Bax and Bcl-2. The weighted mean difference (WMD) was generated for continuous variables. The relative outcomes were analyzed with the aid of Get Data Graph Digitizer 2.26 and software STATA version 16.0 MP. Results: For the primary endpoint, compared with the modeling group, β-asarone significantly decreased the escape latency (WMD = -12.61, 95% CI: -18.66 to -6.57) and increased the times of crossing platform (WMD = 1.50, 95% CI: 0.31–2.70). For the secondary endpoint, β-asarone remarkably reduced the relative expression of the amyloid precursor protein (APP) (WMD = −2.25, 95% CI: −2.49 to −2.01), decreased the expression of the apoptosis-related protein, associated X protein (Bax) (WMD = −2.40, 95% CI: −3.51 to −1.29), lowered the expression of apoptosis-related protein, B-cell lymphoma-2 (Bcl-2) (WMD = 0.42, 95% CI: 0.38–0.46), and decreased the signal pathway-related proteins, phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) (WMD = −0.70, 95% CI: −0.93 to −0.47) over the control group. Conclusion: β-asarone spectacularly improved the learning ability and memory in rats and mice, which might be correlated with its potential neuroprotective effect through multiple signaling pathways.
format Online
Article
Text
id pubmed-9471869
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-94718692022-09-15 Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis Du, Xin-Yuan Cao, Yu-Shuang Yang, Juan Guo, Li-Chen Zhang, Tong Yuan, Qing Chen, Xi Hu, Li-min Front Pharmacol Pharmacology Background: Currently, there are many different drugs to improve Alzheimer’s disease (AD) from different pathways. As a supplement and alternative medicine, traditional Chinese medicine (TCM) targets multiple pathways which may be different from classical Western medicine, which may be orchestrated with Western medicine to materialize multiplying efficacy in AD patients. Objective: To investigate the therapeutic effect and assess the available preclinical evidence and possible mechanisms of β-asarone which was extracted from Acorus gramineus Soland (Araceae, AGS) for AD based on rat and mouse animal models. Methods: PubMed, Embase, Scopus, Cochrane Library, BIOSIS Previews, Web of Science, EBSCO, and Google Scholar were searched from inception to 5 May 2022. Rat and mouse experiments assessing the therapeutic effects of β-asarone for AD were included. Primary outcomes were neuroethology, including escape latency and times of crossing platform. Second outcomes were cell apoptosis, including Bax and Bcl-2. The weighted mean difference (WMD) was generated for continuous variables. The relative outcomes were analyzed with the aid of Get Data Graph Digitizer 2.26 and software STATA version 16.0 MP. Results: For the primary endpoint, compared with the modeling group, β-asarone significantly decreased the escape latency (WMD = -12.61, 95% CI: -18.66 to -6.57) and increased the times of crossing platform (WMD = 1.50, 95% CI: 0.31–2.70). For the secondary endpoint, β-asarone remarkably reduced the relative expression of the amyloid precursor protein (APP) (WMD = −2.25, 95% CI: −2.49 to −2.01), decreased the expression of the apoptosis-related protein, associated X protein (Bax) (WMD = −2.40, 95% CI: −3.51 to −1.29), lowered the expression of apoptosis-related protein, B-cell lymphoma-2 (Bcl-2) (WMD = 0.42, 95% CI: 0.38–0.46), and decreased the signal pathway-related proteins, phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) (WMD = −0.70, 95% CI: −0.93 to −0.47) over the control group. Conclusion: β-asarone spectacularly improved the learning ability and memory in rats and mice, which might be correlated with its potential neuroprotective effect through multiple signaling pathways. Frontiers Media S.A. 2022-08-31 /pmc/articles/PMC9471869/ /pubmed/36120381 http://dx.doi.org/10.3389/fphar.2022.956746 Text en Copyright © 2022 Du, Cao, Yang, Guo, Zhang, Yuan, Chen and Hu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Du, Xin-Yuan
Cao, Yu-Shuang
Yang, Juan
Guo, Li-Chen
Zhang, Tong
Yuan, Qing
Chen, Xi
Hu, Li-min
Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
title Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
title_full Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
title_fullStr Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
title_full_unstemmed Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
title_short Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
title_sort preclinical evidence and possible mechanisms of β-asarone for rats and mice with alzheimer’s disease: a systematic review and meta-analysis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9471869/
https://www.ncbi.nlm.nih.gov/pubmed/36120381
http://dx.doi.org/10.3389/fphar.2022.956746
work_keys_str_mv AT duxinyuan preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis
AT caoyushuang preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis
AT yangjuan preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis
AT guolichen preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis
AT zhangtong preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis
AT yuanqing preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis
AT chenxi preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis
AT hulimin preclinicalevidenceandpossiblemechanismsofbasaroneforratsandmicewithalzheimersdiseaseasystematicreviewandmetaanalysis